Nilvadipine - Archer Pharmaceuticals

Drug Profile

Nilvadipine - Archer Pharmaceuticals

Alternative Names: ARC 029

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Archer Pharmaceuticals
  • Class Antidementias; Antihypertensives; Dihydropyridines; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 10 Feb 2016 Nilvadipine is still in phase III trial for Alzheimer's Disease (In adults, In elderly) in France, Germany, Greece, Hungary, Ireland, Italy, Sweden, United Kingdom and the Netherlands (NCT02017340)
  • 30 Jan 2014 No development reported - Phase-I for Alzheimer's disease in USA (PO)
  • 31 Oct 2012 Phase-III clinical trials in Alzheimer's disease (In adults, In elderly) in United Kingdom, Sweden, Netherlands, Italy, Ireland, Hungary, Greece, Germany, France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top